Back to Search
Start Over
349TiP EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nab-PTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation
- Source :
-
Annals of Oncology . 2020 Supplement 4, Vol. 31, pS387-S388. 2p. - Publication Year :
- 2020
- Subjects :
- *TRIPLE-negative breast cancer
*PTEN protein
*PLACEBOS
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 31
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 152695034
- Full Text :
- https://doi.org/10.1016/j.annonc.2020.08.451